NFKB1 and neoplasm: In addition to inhibiting key components of the NF‐κB pathway, targeting TNF‐α, which acts as an activator and effector of the NF‐κB pathway, is also expected to achieve the goal of suppressing tumor growth [44, 45, 46, 47].